Clinical Trial Update: Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating Edaravone Dexborneol Sublingual Tablet for post-stroke cognitive impairment in acute ischemic stroke patients is sponsored by Simc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Cognitive Impairment
• Stroke

Drugs mentioned

• Edaravone Dexborneol Sublingual Tablet (edaravone dexborneol)

Snippet

Sponsor: Simcere Pharmaceutical Co., Ltd | Conditions: Post-stroke Cognitive Impairment | Phase 2 | Status: RECRUITING